Parkinson’s Disease Therapeutics - Booming or Bursting!

1
Parkinsons Disease Therapeutics in Major
Developed Markets to 2021 
Published on 11 February, 2016 Single
User Price 4995 No of Pages 136
The report focuses on global major leading
industry players with information such as company
profiles, product picture and specifications,
sales, market share and contact information.
Whats more, the Parkinsons Disease Therapeutics
in Major Developed Markets to 2021 development
trends and marketing channels are analyzed.
2
Summary Parkinson's Disease (PD) is a
progressive, chronic neurodegenerative condition,
which is currently incurable. It is associated
with old age, and characterized by the loss of
neurons in the substantia nigra region of the
brain. The global Parkinson's Disease (PD)
prevalence was estimated at 16.1 million in 2011,
and after Alzheimer's disease it is the second
most common neurodegenerative disease worldwide.
3
Parkinson's Disease (PD) is a progressive disease
and, although not fatal, it can develop severe
symptoms and complications that significantly
impact upon the patient's quality of life.
Symptoms for each stage can be categorized into
early, moderate and advanced stages. Major motor
symptoms of Parkinson's Disease (PD) include
tremors and difficulty walking. Parkinson's
Disease (PD) also gives rise to non-motor
symptoms, such as dementia, depression,
hallucinations and loss of taste and smell.
Click Here To Check Complete Report
4
Scope - A brief introduction to Parkinsons
Disease (PD), including pathogenesis, disease
staging, diagnosis and treatment algorithms -
Comprehensive analysis of the drugs available for
the treatment of PD, covering their safety,
efficacy, treatment patterns, and
strengths/weaknesses, as well as a heat map
comparing drugs in terms of safety and efficacy -
Comprehensive analysis of the pipeline for
Parkinsons Disease (PD) therapies, including
individual analysis of a number of late-stage
pipeline drugs that are likely to enter the
market in the forecast period, on the basis of
Phase distribution, molecule type and molecular
target
5

• - Additional thorough analysis of pipeline drug
  clinical trials by Phase, molecule type, trial
  size, trial duration, and program failure rate
  for each molecule type and mechanism of action
• - Multi-scenario market forecast data to 2021,
  taking into account how it will be affected by
  the introduction of new drugs, the expiry of key
  patents on current drugs, and changes in disease
  epidemiology across the key developed markets of
  the US, Canada, Japan, Germany, the UK, France,
  Italy and Spain
• - Discussion of the drivers of and barriers to
  market growth

Download Sample Brochure
6
Reasons to buy - Understand the different levels
of Parkinsons Disease (PD) therapy from
early-stage to advanced - Understand the vast
scope of the pipeline, including which molecule
types and mechanisms of action are prominent -
Observe the trends in clinical trial duration and
size among clinical Phases and molecule types,
and use the clinical trial failure rate analysis
to assess the risk profiles of current and/or
forthcoming developmental programs for
Parkinsons Disease (PD) therapeutics
7

• - Observe the trends in clinical trial duration
  and size among clinical Phases, between molecule
  types and mechanisms of action, and use the
  clinical trial failure rate analysis to assess
  the risk profiles of current and/or future
  developmental programs for Parkinsons Disease
  (PD) therapeutics
• - Assess the potential clinical and commercial
  impact of current late-stage pipeline molecules
  on the Parkinsons Disease (PD) therapeutics
  market

Make an Inquiry Before Buying
8
Key questions answered in this report  What
will the market size be in 2020 and what will the
growth rate be? What are the key market
trends? What is driving this market? What are
the challenges to market growth? Who are the
key vendors in this market space? What are the
market opportunities and threats faced by the key
vendors? What are the strengths and weaknesses
of the key vendors? You can request one free
hour of our analysts time when you purchase this
market report. Details are provided within the
report.
9
Parkinsons Disease Therapeutics in Major
Developed Markets to 2021
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Parkinsons Disease Therapeutics in Major
Developed Markets to 2021 and future
opportunities are provided in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Parkinsons Disease
Therapeutics in Major Developed Markets to 2021